EUCTR2008-005825-12-ES进行中（未招募）不适用
Ensayo clinico de fase 3, multicéntrico, en abierto y con cambio de tratamiento para evaluar la seguridad y eficacia de Glucocerebrosidasa Humana Recombinante expresada en células vegetales (prGCD) en pacientes con enfermedad de Gaucher tratados con Imiglucerasa (Cerezyme®) como terapia de reemplazo enzimatico. A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated with Imiglucerase (Cerezyme®) Enzyme Replacement Therapy - NA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males and females, 18 years or older
- •2. Female patients of child-bearing potential and male patients with female partners of child-bearing potential must agree to use a medically acceptable method of contraception, not including the rhythm method
- •3. Diagnosis of Gaucher disease with leukocyte GCD activity level ?3 nmol/mg*hr (?30 % of the mean activity of the reference range)
- •4.Stable Gaucher disease, defined as:
- •a. Hemoglobin during Stability Evaluation Period is stable with no value more than 15% below or above the mean value
- •b. Platelets count during Stability Evaluation Period is stable with no values more than 40% below or above the mean value if the mean value is >120,000, or more than 20% below or above the mean value if the mean value is ? 120,000
- •c. No major surgery in the last year
- •d. No blood transfusion or major bleeding episode in the last year
- •e. No acute avascular necrosis event in the last year
- •f. No evidence of spleen or liver increasing enlargement while being treated with enzyme replacement therapy by palpation, ultrasound, or MRI over the last year
- •5. Receiving imiglucerase therapy for at least 2 years and on a stable maintenance regimen (dose unchanged) for at least last six months
- •6. Able to provide written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Currently taking another experimental drug for any condition
- •2. Pregnant or nursing or planning to become pregnant
- •3. History of allergy to carrots
- •4. Presence of anti-glucocerebrosidase (GCD) antibodies
- •5. Previous infusion reaction suspected to be allergic in nature to Cerezyme® or Ceredase® or receiving premedication to prevent infusion reactions
- •6. Presence of HIV and/or HBsAg and/or hepatitis C infection
- •7. Presence of unresolved anemia due to iron, folic acid or vitamin B12 deficiency
- •8. Presence of any significant comorbidity that could confound the interpretation of the clinical response to prGCD
- •9. Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the patient?s compliance with the requirements of the study.
研究者
相似试验
进行中（未招募）
1 期
Ensayo clínico en fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad, la tolerabilidad, la eficacia y la inmunogenicidad de V212 en receptores de autotrasplantes de células hematopoyéticas (auto-TCH) ; A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trialto Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients ofAutologous Hematopoietic Cell Transplants (HCTs)Incidencia de Herpes Zoster en receptores de autotrasplantes de células hematopoyéticas(auto-TCH)/Incidence of Herpes Zoster in recipients of Autologous HCTsMedDRA version: 13Level: LLTClassification code 10019974Term: Herpes zosterEUCTR2010-020150-34-ESMerck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc1,200
进行中（未招募）
不适用
Ensayo clinico de fase III, multicéntrico, aleatorizado, doble ciego; para evaluar la seguridad y eficacia de dos grupos paralelos de dosis de glucocerebrosidasa humana recombinante expresada en células vegetales (prGCD) en pacientes con enfermedad de Gaucher.A phase III Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease. - NAEUCTR2007-000498-42-ESProtalix Biotherapeutics30
进行中（未招募）
不适用
Ensayo clínico multicéntrico en Fase III, randomizado, doble-ciego, controlado con placebo, de Rebif New Formulation (44 mcg tres veces por semana y 44 mcg una vez por semana) en pacientes con alto riesgo de conversión a esclerosis múltiple.A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - Rebif FLEXible dosing in early Multiple Sclerosis (REFLEX)EUCTR2006-002982-38-ESMerck Serono S.A. - Geneva, an affiliate of Merck KGaA Darmstadt, Germany480
进行中（未招募）
1 期
Ensayo clínico en fase III multicéntrico, doble ciego, aleatorizado y con control activo para evaluar la seguridad y la eficacia de raltegravir (MK-0518) administrado una vez al día frente a raltegravir administrado dos veces al día, cada uno en combinación con TRUVADA?, en pacientes infectados por el VIH no tratados previamente A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK-0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA?, in Treatment-Naïve HIV Infected Patients - Safety and efficacy of once daily raltegravir compared to twice daily raltegravirEUCTR2008-002733-70-ESMerck & Co., Inc.750
进行中（未招募）
1 期
Ensayo clínico de fase III multicéntrico, randomizado, doble ciego, controlado con placebo, para comparar la eficacia de bevacizumab en combinación con rituximab y CHOP (RA CHOP) frente a rituximab y CHOP (R CHOP) en pacientes con linfoma difuso de células B grandes (LDCBG) CD20 positivo no tratados previamente.A multi-center, randomized, double-blind, placebo-controlled phase III trial omparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL) - MAIEUCTR2006-005520-16-ESF. Hoffmann-La Roche Ltd1,060